Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.

RPEP-082082024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.
Published In:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(9), 1416-1422 (2024)
Database ID:
RPEP-08208

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-08208·https://rethinkpeptides.com/research/RPEP-08208

APA

Fosse, Aurelien; Hadoux, Julien; Girot, Paul; Beron, Amandine; Afchain, Pauline; Cottereau, Anne-Segolene; Baudin, Eric; Dierickx, Lawrence O; Lecomte, Thierry; Perrier, Marine; Lepage, Come; Bouhier-Leporrier, Karine; Goichot, Bernard; Lachachi, Boumediene; Walter, Thomas; Durand, Alice. (2024). Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(9), 1416-1422. https://doi.org/10.2967/jnumed.123.267363

MLA

Fosse, Aurelien, et al. "Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.." Journal of nuclear medicine : official publication, 2024. https://doi.org/10.2967/jnumed.123.267363

RethinkPeptides

RethinkPeptides Research Database. "Peptide Receptor Radionuclide Therapy or Everolimus in Metas..." RPEP-08208. Retrieved from https://rethinkpeptides.com/research/fosse-2024-peptide-receptor-radionuclide-therapy

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.